Triheptanoin treatment in ataxia-telangiectasia: the significance of innovative clinical trials targeting mitochondrial dysfunction.
作者信息
Onodera Osamu
机构信息
Department of Neurology, Brain Research Institute, Niigata University, Niigata, Japan.
出版信息
EBioMedicine. 2025 Aug 8;119:105882. doi: 10.1016/j.ebiom.2025.105882.
Abstract
摘要
相似文献
1
Triheptanoin treatment in ataxia-telangiectasia: the significance of innovative clinical trials targeting mitochondrial dysfunction.三庚酸甘油酯治疗共济失调毛细血管扩张症：针对线粒体功能障碍的创新型临床试验的意义
EBioMedicine. 2025 Aug 8;119:105882. doi: 10.1016/j.ebiom.2025.105882.
2
Phase 2a/b randomised placebo-controlled dose-escalation trial of triheptanoin for ataxia-telangiectasia: treating mitochondrial dysfunction with anaplerosis.庚酸甘油酯用于共济失调毛细血管扩张症的2a/b期随机安慰剂对照剂量递增试验：通过回补作用治疗线粒体功能障碍
EBioMedicine. 2025 Jul 4;118:105840. doi: 10.1016/j.ebiom.2025.105840.
3
Compound heterozygous variants including a novel copy number variation in a child with atypical ataxia-telangiectasia: a case report.患儿存在非典型性毛细血管扩张共济失调症，携带复合杂合变异，包括一种新的拷贝数变异：病例报告。
BMC Med Genomics. 2021 Aug 17;14(1):204. doi: 10.1186/s12920-021-01053-3.
4
A pharmacological profile of triheptanoin for the treatment of long-chain fatty acid oxidation disorders.三庚酸甘油酯治疗长链脂肪酸氧化障碍的药理学概况。
Expert Rev Clin Pharmacol. 2025 Jul;18(7):449-460. doi: 10.1080/17512433.2025.2528835. Epub 2025 Jul 15.
5
ATAXIA TELANGIECTASIA MUTATED PROTECTS AGAINST LIPOPOLYSACCARIDE-INDUCED BLOOD-BRAIN BARRIER DISRUPTION BY REGULATING ATK/DRP1-MEDIATED MITOCHONDRIAL HOMEOSTASIS.突变型共济失调毛细血管扩张症通过调节 ATK/DRP1 介导的线粒体稳态来防止脂多糖诱导的血脑屏障破坏。
Shock. 2023 Jul 1;60(1):100-109. doi: 10.1097/SHK.0000000000002139. Epub 2023 May 5.
6
Drug repurposing screen for the rare disease ataxia-telangiectasia.针对罕见病共济失调毛细血管扩张症的药物重新利用筛选。
SLAS Discov. 2025 Jan;30:100200. doi: 10.1016/j.slasd.2024.100200. Epub 2024 Dec 4.
7
Reduced levels of MRE11 cause disease phenotypes distinct from ataxia telangiectasia-like disorder.MRE11 水平降低导致不同于共济失调毛细血管扩张症样疾病表型。
Hum Mol Genet. 2024 Sep 3;33(18):1605-1617. doi: 10.1093/hmg/ddae101.
8
Sarcoidosis-like Skin Lesions as the First Manifestation of Ataxia-Telangiectasia.结节病样皮肤病变作为共济失调毛细血管扩张症的首发表现
Children (Basel). 2025 May 23;12(6):672. doi: 10.3390/children12060672.
9
An anaplerotic approach to correct the mitochondrial dysfunction in ataxia-telangiectasia (A-T).采用补料策略纠正共济失调毛细血管扩张症（A-T）中的线粒体功能障碍。
Mol Metab. 2021 Dec;54:101354. doi: 10.1016/j.molmet.2021.101354. Epub 2021 Oct 9.
10
Factors Influencing the Central Nervous System (CNS) Distribution of the Ataxia Telangiectasia Mutated and Rad3-Related Inhibitor Elimusertib (BAY1895344): Implications for the Treatment of CNS Tumors.影响共济失调毛细血管扩张突变和 Rad3 相关抑制剂依鲁替尼（BAY1895344）在中枢神经系统（CNS）分布的因素：对中枢神经系统肿瘤治疗的影响。
J Pharmacol Exp Ther. 2024 Oct 18;391(2):346-360. doi: 10.1124/jpet.123.002002.
本文引用的文献
1
Phase 2a/b randomised placebo-controlled dose-escalation trial of triheptanoin for ataxia-telangiectasia: treating mitochondrial dysfunction with anaplerosis.庚酸甘油酯用于共济失调毛细血管扩张症的2a/b期随机安慰剂对照剂量递增试验：通过回补作用治疗线粒体功能障碍
EBioMedicine. 2025 Jul 4;118:105840. doi: 10.1016/j.ebiom.2025.105840.
2
Safety and efficacy of intra-erythrocyte dexamethasone sodium phosphate in children with ataxia telangiectasia (ATTeST): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial.经红细胞内磷酸地塞米松钠治疗共济失调毛细血管扩张症（ATTeST）患儿的安全性和有效性：一项多中心、随机、双盲、安慰剂对照的 3 期临床试验。
Lancet Neurol. 2024 Sep;23(9):871-882. doi: 10.1016/S1474-4422(24)00220-5.
3
An anaplerotic approach to correct the mitochondrial dysfunction in ataxia-telangiectasia (A-T).采用补料策略纠正共济失调毛细血管扩张症（A-T）中的线粒体功能障碍。
Mol Metab. 2021 Dec;54:101354. doi: 10.1016/j.molmet.2021.101354. Epub 2021 Oct 9.
4
Cellular functions of the protein kinase ATM and their relevance to human disease.蛋白激酶 ATM 的细胞功能及其与人类疾病的相关性。
Nat Rev Mol Cell Biol. 2021 Dec;22(12):796-814. doi: 10.1038/s41580-021-00394-2. Epub 2021 Aug 24.
5
Neurofilament light chain: A novel blood biomarker in patients with ataxia telangiectasia.神经丝轻链：共济失调毛细血管扩张症患者的新型血液生物标志物。
Eur J Paediatr Neurol. 2021 May;32:93-97. doi: 10.1016/j.ejpn.2021.04.002. Epub 2021 Apr 9.
6
NAD supplementation prevents STING-induced senescence in ataxia telangiectasia by improving mitophagy.烟酰胺腺嘌呤二核苷酸（NAD）补充通过改善线粒体自噬预防共济失调毛细血管扩张症中由干扰素基因刺激蛋白（STING）诱导的衰老。
Aging Cell. 2021 Apr;20(4):e13329. doi: 10.1111/acel.13329. Epub 2021 Mar 18.
7
ATM inhibition enhances cancer immunotherapy by promoting mtDNA leakage and cGAS/STING activation.ATM 抑制通过促进 mtDNA 泄漏和 cGAS/STING 激活增强癌症免疫治疗。
J Clin Invest. 2021 Feb 1;131(3). doi: 10.1172/JCI139333.
8
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.尼达尼布治疗进行性纤维化间质性肺疾病。
N Engl J Med. 2019 Oct 31;381(18):1718-1727. doi: 10.1056/NEJMoa1908681. Epub 2019 Sep 29.
9
NAD Replenishment Improves Lifespan and Healthspan in Ataxia Telangiectasia Models via Mitophagy and DNA Repair.烟酰胺腺嘌呤二核苷酸（NAD）补充通过线粒体自噬和DNA修复改善共济失调毛细血管扩张症模型的寿命和健康寿命。
Cell Metab. 2016 Oct 11;24(4):566-581. doi: 10.1016/j.cmet.2016.09.004.
Zotero 插件